BACKGROUND: The clinicoepidemiologic relevance of moderately elevated concentrations of circulating beta(2)-microglobulin (beta(2)-M) has not been established. METHODS: We examined whether serum beta(2)-M concentration independently predicts total mortality in community-dwelling older populations and compared its predictive value with that of cystatin C and C-reactive protein (CRP) using a prospective cohort study of 1034 initially nondisabled persons 65 years and older as part of the Tokyo Metropolitan Institute of Gerontology Longitudinal Interdisciplinary Study on Aging. Cox proportional hazards models were used to examine independent associations between baseline beta(2)-M levels and total mortality. RESULTS: During a median follow-up of 7.9 years, 223 persons died. A strong dose-response relationship was found between baseline serum beta(2)-M concentration and mortality risk, even after multiple adjustments. Compared with individuals in the lowest tertile of serum beta(2)-M concentration, those in the middle (hazard ratio, 2.02; 95% confidence interval [CI], 1.35-3.04) and highest (hazard ratio, 2.84; 95% CI, 1.92-4.20) tertiles had a substantially increased mortality risk. Respective values were 1.28 (95% CI, 0.86-1.90) and 1.95 (95% CI, 1.31-2.89) for cystatin C and 1.39 (95% CI, 0.98-1.98) and 1.44 (95% CI, 1.00-2.06) for CRP; only the highest tertiles showed significantly higher mortality risks. The area under the receiver operating characteristic curve for 8-year mortality was greatest for beta(2)-M (0.70; 95% CI, 0.66-0.74), followed by cystatin C (0.66; 95% CI, 0.62-0.70) and CRP (0.57; 95% CI, 0.53-0.61). Additional adjustment for renal function measures, inflammation markers, or both only partially reduced the association between beta(2)-M and mortality. CONCLUSION: Serum beta(2)-M is an independent predictor of total mortality in a general population of older adults and may be a better predictor than cystatin C or CRP.
BACKGROUND: The clinicoepidemiologic relevance of moderately elevated concentrations of circulating beta(2)-microglobulin (beta(2)-M) has not been established. METHODS: We examined whether serum beta(2)-M concentration independently predicts total mortality in community-dwelling older populations and compared its predictive value with that of cystatin C and C-reactive protein (CRP) using a prospective cohort study of 1034 initially nondisabled persons 65 years and older as part of the Tokyo Metropolitan Institute of Gerontology Longitudinal Interdisciplinary Study on Aging. Cox proportional hazards models were used to examine independent associations between baseline beta(2)-M levels and total mortality. RESULTS: During a median follow-up of 7.9 years, 223 persons died. A strong dose-response relationship was found between baseline serum beta(2)-M concentration and mortality risk, even after multiple adjustments. Compared with individuals in the lowest tertile of serum beta(2)-M concentration, those in the middle (hazard ratio, 2.02; 95% confidence interval [CI], 1.35-3.04) and highest (hazard ratio, 2.84; 95% CI, 1.92-4.20) tertiles had a substantially increased mortality risk. Respective values were 1.28 (95% CI, 0.86-1.90) and 1.95 (95% CI, 1.31-2.89) for cystatin C and 1.39 (95% CI, 0.98-1.98) and 1.44 (95% CI, 1.00-2.06) for CRP; only the highest tertiles showed significantly higher mortality risks. The area under the receiver operating characteristic curve for 8-year mortality was greatest for beta(2)-M (0.70; 95% CI, 0.66-0.74), followed by cystatin C (0.66; 95% CI, 0.62-0.70) and CRP (0.57; 95% CI, 0.53-0.61). Additional adjustment for renal function measures, inflammation markers, or both only partially reduced the association between beta(2)-M and mortality. CONCLUSION: Serum beta(2)-M is an independent predictor of total mortality in a general population of older adults and may be a better predictor than cystatin C or CRP.
Authors: Brad C Astor; Tariq Shafi; Ron C Hoogeveen; Kunihiro Matsushita; Christie M Ballantyne; Lesley A Inker; Josef Coresh Journal: Am J Kidney Dis Date: 2012-02-04 Impact factor: 8.860
Authors: Anna E Prizment; Amy M Linabery; Pamela L Lutsey; Elizabeth Selvin; Heather H Nelson; Aaron R Folsom; Timothy R Church; Charles G Drake; Elizabeth A Platz; Corinne Joshu Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02-05 Impact factor: 4.254
Authors: Adrienne Tin; Brad C Astor; Eric Boerwinkle; Ron C Hoogeveen; Josef Coresh; Wen Hong Linda Kao Journal: Hum Genet Date: 2013-02-16 Impact factor: 4.132
Authors: Kevin T Nead; Margaret J Zhou; Roxanne Diaz Caceres; Stephen J Sharp; Mackenzie R Wehner; Jeffrey W Olin; John P Cooke; Nicholas J Leeper Journal: Am J Cardiol Date: 2013-01-01 Impact factor: 2.778
Authors: Ross L Prentice; Sophie Paczesny; Aaron Aragaki; Lynn M Amon; Lin Chen; Sharon J Pitteri; Martin McIntosh; Pei Wang; Tina Buson Busald; Judith Hsia; Rebecca D Jackson; Jacques E Rossouw; Joann E Manson; Karen Johnson; Charles Eaton; Samir M Hanash Journal: Genome Med Date: 2010-07-28 Impact factor: 11.117